Tag: CathWorks

Medtronic completes acquisition of CathWorks, expanding its leadership in transforming care for patients with cardiovascular disease

CathWorks FFRangio® System employs drug-free, wire-free technology for comprehensive physiological assessment GALWAY, Ireland, April 20, 2026 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has completed its acquisition of CathWorks,…

Late-Breaking Clinical Trial Presentation of the First-Ever US Cohort of Over 4,000 CathWorks FFRangio Patients Demonstrates Similar Clinical Outcomes to Invasive Pressure Wire-Guided PCI through 2 Years

WASHINGTON, March 7, 2026 /PRNewswire/ — Today at the Cardiovascular Research Technologies (CRT) annual conference taking place in Washington, DC, Dr. Christopher Chieh Yang Koo from National University Hospital Singapore, on behalf of investigators from Smith Center for Outcomes…

Medtronic advances its innovation strategy with intent to acquire CathWorks

Deal demonstrates Medtronic’s commitment to expanding pipeline through strategic investments and targeted acquisitions Exercising option to acquire will bolster Medtronic’s interventional cardiology portfolio, expanding its leadership in transforming how cardiovascular disease is diagnosed and treated Medtronic’s intent to acquire follows a 2022 strategic partnership agreement with CathWorks GALWAY, Ireland, Feb. 3, 2026 /PRNewswire/ — Medtronic plc (NYSE:MDT), […]

PROVISION Study, First Ever Prospective RCT of CathWorks FFRangio Outcomes Compared to Invasive Wire-based Physiology in Japan, Meets its Primary Endpoint

PROVISION Study demonstrates significant economic and resource utilization advantages in FFRangio cohort compared to invasive wire-based FFR cohort WASHINGTON, Oct. 27, 2024 /PRNewswire/ — Today at the Cardiovascular Research Foundation’s annual Transcatheter Cardiovascular Therapeutics…

Fort Sanders Regional Medical Center First in Tennessee to Adopt New Cardiac Angiogram Technology

KNOXVILLE, Tenn., June 26, 2024 /PRNewswire/ — Fort Sanders Regional Medical Center, a member of Knoxville-based Covenant Health, was the first hospital in the state of Tennessee to adopt revolutionary diagnostic technology that provides clinicians with a patient’s physiology results in just a few minutes.
Coronary heart disease is one of the top killers of adults in the U.S. and particularly the Southeast. Quick diagnosis and intervention are key to treating cardiac patients who are suffering from heart disease, heart attack, or other events causing blockages in arteries that can be life-threatening.
Fort Sanders Regional’s cardiac catheterization lab is staffed around the clock, 24/7, treating both heart patients who have been admitted to the hospital and those who are having outpatient procedures.
When a patient presents with a potential artery blockage, the heart team at Fort Sanders Regional can use a new tool that shows doctors exactly what percentage of an artery is blocked. The CathWorks FFRangio ® System is a computer-based technology that uses routine angiograms (images) of a patient’s heart structure to create a 3D model showing the location and degree of any blockages and their coronary arteries. This helps providers more quickly diagnose and intervene as needed, including determining whether the patient needs a stent and where the stent should be placed in the heart structure.
Fractional flow reserve (FFR) is a diagnostic measurement that evaluates the physiologic impact of coronary artery narrowing due to cholesterol plaque. It is an important part of the decision-making process to decide if a stent placement is indicated and the length of the stent when managing patients with coronary artery disease (CAD).
In contrast to traditional FFR, the FFRangio System combines artificial intelligence (AI) and advanced computational science to obtain quick and reliable FFRangio values from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires. The system provides physicians intraprocedural FFRangio values for all coronary arteries.
Josh Todd, MD, interventional cardiologist at Fort Sanders Regional, said, “With this new tool, interventional cardiologists can perform clinical assessments quicker, more comprehensively, without medications, and in a way that’s seamless and more efficient to the patient. This cutting-edge technology will transform how cardiovascular disease is diagnosed and treated.”
To view the full release, visit https://www.covenanthealth.com/blog/cathworks-technology/.
SOURCE Covenant Health

CathWorks Announces First Patient Enrolled in Global ALL-RISE Study

Global clinical study aims to broaden evidence base by assessing clinical and economic benefits for the FFRangio System First patient enrolled at Ascension St. John Hospital in Michigan KFAR-SABA, Israel and IRVINE, Calif., June 28, 2023 /PRNewswire/ — CathWorks announced today that the first patient has been enrolled in the Advancing Cath Lab Results with FFRangio Coronary Physiology […]

Fourth Generation CathWorks FFRangio® System Receives Regulatory Approval in Japan

KFAR-SABA, Israel and IRVINE, Calif., Oct. 6, 2022 /PRNewswire/ — CathWorks announced today the approval of the fourth generation CathWorks FFRangio® System by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). The FFRangio System is also commercially available in the United States and Europe. “The FFRangio System enables us to quickly perform a comprehensive physiologic assessment of coronary artery […]

Medtronic announces co-promotion agreement with CathWorks, with path toward acquisition

  Partnership underscores Medtronic’s commitment to investing in innovative technologies that support physicians and patients from diagnosis to treatment CathWorks’ FFRangio® System provides diagnostic and physiologic information through artificial intelligence to potentially disrupt traditional FFR and revolutionize the management of coronary artery disease DUBLIN and KEFAR SAVA, Israel, July 12, 2022 /PRNewswire/ — Medtronic […]

CathWorks and Quest International Announce Global Post-Sales Technical Service Support Partnership

KFAR-SABA, Israel and IRVINE, Calif., April 6, 2022 /PRNewswire/ — CathWorks, an original equipment manufacturer (OEM), and Quest International, a global service support provider to the OEMs, announced today they have signed a post-sales technical service support agreement that Quest International becomes the preferred technical service delivery partner for end-to-end service support of CathWorks’ fast-growing […]

CathWorks Presents New Data and Latest Innovations at ACC 2022

CathWorks FFRangio™ System outcomes study to be presented at ACC 2022 CathWorks announces the completion of more than 5,000 FFRangio cases globally KFAR-SABA, Israel and IRVINE, Calif., March 31, 2022 /PRNewswire/ — CathWorks announced today that the results of its most recent outcomes study on the CathWorks FFRangio™ system will be presented by Dr. Guy Witberg from Rabin Medical […]